IAG’ Scientific Research Team Presenting at the 2018 British Neuro-Oncology Society Conference
Dr. Diana Roettger, Head of Scientific and Medical Affairs at Image Analysis Group (IAG), is meeting with key biotech companies at the British Neuro-Oncology Society Conference (BNOS) at the University of Winchester from July 4-6, 2018. Dr. Roettger will meet with Key Opinion Leaders to further understand the role of imaging in Brain Cancer Studies and focus on both the clinical and scientific aspects of Neuro-Oncology.
The IAG team will be presenting our work The Role Dynamic Susceptibility Contrast Perfusion- Weighted MRI Reliable in the Estimation of IDH Mutation in Gliomas. In this study, we aimed to investigate whether Dynamic Susceptibility Contrast Perfusion- Weighted Imaging (DSC – PWI), enhanced by texture analysis and machine learning, can stratify gliomas according to their IDH mutation status.
To join our conversation or schedule a meeting at BNOS please email: firstname.lastname@example.org
About BNOS Conference
The annual BNOS conference takes place at various UK locations and runs over three days. This major event ensures that all those working in neuro-oncology in the UK meet to learn, discuss, and impart new findings within a friendly and informal atmosphere. The multidisciplinary role of BNOS is represented by plenary sessions, presentations, discussions, debates, sponsored symposia, meet-the-expert sessions, role-play and posters covering a wide variety of topics which may range from stem cells and in-vitro models to classification and biomarkers, neuro-imaging and neuro-surgical techniques, immuno-oncology, quality of life and indicators of patient performance. Learn more at https://www.bnos.org.uk/events/bnos-conference/
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin
Join us at BIO International Convention in Boston 5th-8th June 2023
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.